Calquence granted US Breakthrough Therapy Designation
14 August 2019 07:00 BST Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia Designation based on positive results from two Phase III trials AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia (CLL), one of the most common types of leukaemia in adults.1 José Baselga, Executive Vice President, Oncology R&D, said: "This is an important regulatory milestone for